Comparative study of non-functional islet cell tumors and pancreatic solid and papillary neoplasms: Biological behavior and immunohistochemistry
Yoon-La Choi
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorYoung Lyun Oh
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorSeok-Hyung Kim
Department of Pathology, Seoul National University School of Medicine, Seoul, Korea
Search for more papers by this authorCheol Keun Park
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorGeunghwan Ahn
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorYoon-La Choi
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorYoung Lyun Oh
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorSeok-Hyung Kim
Department of Pathology, Seoul National University School of Medicine, Seoul, Korea
Search for more papers by this authorCheol Keun Park
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorGeunghwan Ahn
Department of Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine and
Search for more papers by this authorAbstract
Although non-functional islet cell tumor (NFICT) and solid and papillary neoplasm (SPN) share similar clinical and pathological features, the outcome of each is different. Because NFICT often follow a malignant course and SPN are usually benign, the correct differential diagnosis is very important. We investigated the clinical and pathological findings in 10 cases of NFICT and 12 cases of SPN, including immunohistochemical analysis for chromogranin, vimentin, neuron-specific enolase, somatostatin, alpha-1-antitrypsin, estrogen receptor, progesterone receptor, CD99, p21 and Ki-67. The current study shows that chromogranin is the most valuable marker in differentiating between the tumors (P < 0.01). In contrast to previous reports stating that SPN express the progesterone and/or estrogen receptors, which are absent in other pancreatic tumors, our results show that one-third of SPN were positive for the progesterone receptor. Downregulation of p21 was found more frequently in NFICT (40%) than SPN (17%). The mean value of the Ki-67 proliferation index for NFICT (2.77% ± 2.53%) was significantly higher than that for SPN (0.94% ± 0.89%; P = 0.043). These results are consistent with NFICT having more malignant behavior than SPN.
References
- 1 Prinz RA, Badrinath R, Chejfee G, Freark RJ, Grenlee HB. ‘Nonfunctioning’ islet cell carcinoma of the pancreas. Am. Surg. 1981; 47: 2500–2502.
- 2 Eckhauser FE, Cheung PS, Vinik AI, Strodel WE, Lloyd RV, Thompson NW. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 1986; 100: 978–988.
- 3 Furukawa H, Mukai K, Kosuge T et al. Nonfunctioning islet cell tumors of the pancreas: clinical, imaging and pathological aspects in 16 patients. Jpn. J. Clin. Oncol. 1998; 28: 255–261.
- 4 Klimstra DS, Wenig BM, Heffess CS. Solid-pseudopapillary tumor of the pancreas: a typically cystic carcinoma of low malignant potential. Semin. Diagn. Pathol. 2000; 17: 66–80.
- 5 Lee WJ, Park YT, Choi JS, Chi HS, Kim BR. Solid and papillary neoplasms of the pancreas. Yonsei Med. J. 1996; 37: 131–141.
- 6 Yamaguchi K, Miyagahara T, Tsuneyoshi M et al. Papillary cystic tumor of the pancreas: an immunohistochemical and ultrastructural study of 14 patients. Jpn. J. Clin. Oncol. 1989; 19: 102–111.
- 7 Wrba F, Chott A, Ludvik B et al. Solid and cystic tumor of the pancreas; a hormonal-dependent neoplasm? Histopathology 1988; 12: 388–400.
- 8 Zamboni G, Bonetti F, Scarpa A et al. Expression of progesterone receptors in solid-cystic tumour of the pancreas: a clinicopathological and immunohistochemical study of ten cases. Virchows Arch. A Pathol. Anat. 1993; 423: 425–431.
- 9 Xiong Y, Hannon GJ, Zhang H, Casso D, Kobyashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1992; 357: 82–85.
- 10 Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br. J. Cancer 1997; 75: 1617–1620.
- 11 Shi YZ, Hui AM, Takayama T, Li Z, Cui Z, Makuuchi M. Reduced p21WAF1/CIP1 expression is predominantly related to altered p53 in hepatocellular carcinomas. Br. J. Cancer 2000; 83: 50–55.
- 12 DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol. 1995; 147: 884–888.
- 13
Dergham ST,
Dugan MC,
Joshi US et al.
The clinical significance of p21WAF1/CIP1 and p53 expression in pancreatic adenocarcinoma.
Cancer
1997; 80: 372–381.DOI: 10.1002/(sici)1097-0142(19970801)80:3<372::aid-cncr4>3.3.co;2-l
10.1002/(SICI)1097-0142(19970801)80:3<372::AID-CNCR4>3.0.CO;2-U PubMed Web of Science® Google Scholar
- 14 Tubiana M, Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother. Oncol. 1989; 15: 1–18.
- 15 Gerders J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferation − associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984; 27: 867–873.
- 16 Lieber MR, Lack EE, Roberts JR Jr et al. Solid and papillary epithelial neoplasms of the pancreas. An ultrastructural and immunocytochemical study of six cases. Am. J. Surg. Pathol. 1987; 11: 85–93.
- 17 Madeira I, Terris B, Voss M et al. Prognostic factors in patients with endocrine tumors of the duodenopancreatic area. Gut 1998; 43: 422–427.
- 18 Konomi K, Chijiiwa K, Katsuta T, Yamaguchi K. Pancreatic somatostatinoma: a case report and review of the literature. J. Surg. Oncol. 1990; 43: 259–265.
- 19
Moertel CG,
Kvols LK,
O'Connell MJ et al.
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin.
Cancer
1991; 68: 227–232.
10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- 20 Miettinen M, Partanen S, Fraki O, Kivilaakso E. Papillary cystic tumor of the pancreas. An analysis of cellular differentiation by electron microscopy and immunohistochemistry. Am. J. Surg. Pathol. 1987; 11: 855–865.
- 21 Delhaye JC, Sperduto N, Rickaert F, Gelin M. Nonfunctioning neuroendocrine tumors of the pancreas: clinical presentation of 7 patients. Hepatogastroenterology 1996; 43: 1640–1644.
- 22 Mao C, Guvendi M, Domenico DR et al. Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Study of three cases and cumulative review of the world's literature. Surgery 1995; 118: 821–828.
- 23
Wilson MB,
Adams DB,
Garen PD et al.
Aspiration cytologic, ultrastructural, and DNA cytometric findings of solid and papillary tumor of the pancreas.
Cancer
1992; 69: 2235–2243.
10.1002/1097-0142(19920501)69:9<2235::AID-CNCR2820690905>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- 24 Marolt VF, Pleskovic L, Pegan V. Solid papillary-cystic tumor of pancreas. Hepatogasteroenterology 1999; 46: 2978–2982.
- 25 Lam KY, Lo CY, Fan ST. Pancreatic solid-cystic-papillary tumor: Clinicopathologic features in eight patients from Hong Kong and review of the literature. World J. Surg. 1999; 23: 1045–1050.
- 26 Lam KY, Lo CY. Pancreatic endocrine tumor: a 22-year clinicopathological experience with morphological immunohistochemical observation and a review of the literature. Eur. J. Surg. Oncol. 1997; 23: 36–42.
- 27 Pettinato G, Manivel JC, Ravetto C et al. Papillary cystic tumor of the pancreas. Am. J. Clin. Pathol. 1992; 98: 478–488.
- 28 Chott A, Klopple G, Buxbaum P, Heitz PU. Neuron specific enolase demonstration in the diagnosis of a solid-cystic (papillary cystic) tumors of the pancreas. Virchows Arch. A Pathol. Anat. Histopathol. 1987; 410: 397–402.
- 29 Vinores SA, Bonnin JM, Rubinstein LJ, Marangos PJ. Immunohistochemical demonstration of neuron-specific enolase in neoplasms of the CNS and other tissues. Arch. Pathol. Lab. Med. 1984; 108: 536–540.
- 30
Matsunou H,
Konishi F.
Papillary-cystic neoplasm of the pancreas. A clinicopathologic study concerning the tumor aging and malignancy of nine cases.
Cancer
1990; 65: 283–291.
10.1002/1097-0142(19900115)65:2<283::AID-CNCR2820650217>3.0.CO;2-X CAS PubMed Web of Science® Google Scholar
- 31 Learmonth GM, Price SK, Visser AE, Emms M. Papillary and cystic neoplasm of the pancreas –An acinar cell tumor? Histopathology 1985; 9: 63–79.
- 32 Miettinen M, Partanen S, Fraki O, Kivilaakso E. Papillary cystic tumor of the pancreas. An analysis of cellular differentiation by electron microscopy and immunohistochemistry. Am. J. Surg. Pathol. 1987; 11: 855–865.
- 33
Morohoshi T,
Kanda M,
Horie A et al.
Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma, and solid cystic (papillary-cystic) tumor.
Cancer
1987; 59: 739–747.
10.1002/1097-0142(19870215)59:4<739::AID-CNCR2820590413>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 34 Du Boulay CEH. Demonstration of alpha-1-antitrypsin and alpha-1-antichymotrypsin in fibrous histiocytomas using the immunoperoxidase technique. Am. J. Surg. Pathol. 1982; 6: 559–564.
- 35 Yamaguchi K, Miyagahara T, Tsuneyoshi M et al. Papillary cystic tumor of the panreas: an immunohistochemical and ultrastructural study of 14 patients. Jpn. J. Clin. Oncol. 1989; 19: 102–111.
- 36 Kimura N, Nakazato Y, Nagura H, Sasano N. Expression of intermediate filaments in neuroendocrine tumors. Arch. Pathol. Lab. Med. 1990; 114: 506–510.
- 37 Kimura N, Sasano N, Namiki T, Nakazato Y. Coexpression of cytokeratin, neurofilament and vimentin in carcinoid tumors. Virchows Arch. A Pathol. Anat. Histopathol. 1989; 415: 69–77.
- 38 Carnone A, Ranelletti FO, Rinelli A et al. Type II estrogen receptors in the papillary cystic tumor of the pancreas. Am. J. Clin. Pathol. 1989; 92: 572–576.
- 39 Von Herbay A, Sieg B, Otto HF. Solid-cystic tumor of the pancreas. An endocrine neoplasm? Virchows. Arch. A Pathol. Anat. Histopathol. 1990; 416: 535–538.
- 40 Morrison DM, Jewell LD, McCaughey WTE, Danylk J, Shnitka TK, Manickael V. Papillary cystic tumor of the pancreas. Arch. Pathol. Lab. Med. 1984; 108: 723–727.
- 41
Ladanyi M,
Mulay S,
Arseneau J,
Bettez P.
Estrogen and progesterone receptor determination in the papillary cystic neoplasm of the pancreas. With immunohistochemical and ultrastructural observations.
Cancer
1989; 60: 1604–1611.
10.1002/1097-0142(19871001)60:7<1604::AID-CNCR2820600731>3.0.CO;2-# PubMed Web of Science® Google Scholar
- 42 Kloppel G, Maurer R, Hofmann E et al. Solid-cystic (papillary-cystic) tumors within and outside the pancreas in men: report of two patients. Virchows Arch. A Pathol. Anat. Histopathol. 1991; 418: 179–183.
- 43 Katz LBK, Ehya H. Aspiration cytology of papillary cystic neoplasm of the pancreas. Am. J. Clin. Pathol. 1990; 94: 328–333.
- 44 Hess E, Cohen C, DeRose PB, Yost BA, Costa MJ. Nonspecificity of p30/32MIC2 immunolocalization with the 013 monoclonal antibody in the diagnosis of Ewing's sarcoma: Application of an algorithmic immunohistochemical analysis. Appl. Immunohistochem. 1997; 5: 94–103.
- 45 Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody 013. Antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am. J. Surg. Pathol. 1994; 18: 486–494.
- 46 El-Deiry WS, Tokino T, Velculescu VE et al. SAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825.
- 47 Harada N, Gansauge S, Gansauge F et al. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the exrpression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in pancreatic cancer. Br. J. Cancer 1997; 76: 299–305.
- 48
Rosa SL,
Sessa F,
Capella C et al.
Prognostic criteria in nonfunctioning pancreatic endocrine tumors.
Virchows Arch. A Pathol. Anat. Histopathol.
1996; 429: 323–333.
10.1007/BF00198436 Google Scholar
- 49 Pelosi G, Bresaola E, Bogina G et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum. Pathol. 1996; 27: 1124–1134.
- 50 Perret AG, Mosnier JF, Buono JP et al. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am. J. Clin. Pathol. 1998; 109: 286–293.